Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Competitiveness And Perfectionism: Common Traits Of Both Athletic Performance And Disordered Eating
Timberline Knolls, one of the country"s leaders in the treatment of eating disorders, is recognizing well-known tennis star, Monica Seles, for disclosing her history with an eating disorder in her new book Get a Grip. Ms. Seles" display of courage and candor has the potential to help many others who have similar struggles, especially young female athletes.
generic viagra online
Healthy Vision Month Focuses On Refractive Eye Errors
May is Healthy Vision Month, which in 2009 focuses on the 60 percent of Americans who have refractive vision problems.
News of the day
Group Banned From Teaching Abstinence-Only Program In Sonoma County, Calif., Public Schools
Free to Be, a federally-funded organization in California that teaches abstinence-only sex education to students, is at the center of a debate with education officials and others in Sonoma County over whether their curriculum is in compliance with state rules requiring that sexual health education programs in public schools be "balanced" and include information on sexually transmitted infections such as HIV and contraception, the Santa Rosa Press Democrat reports. Sonoma County Office of Education officials in May banned the group from giving any further presentations on public school campuses, citing state law. Free to Be, as well as several school superintendents from around the county, said they are currently reviewing their legal options (Benefield, Santa Rosa Press Democrat, 6/7).
Sexual Health

Senesco Presents Pre-Clinical Multiple Myeloma Data At The 12th Annual Meeting Of The American Society Of Gene Therapy

Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced that Richard Dondero, Vice President of Research and Development, will be presenting pre-clinical data from Senesco"s multiple myeloma studies at the 12th Annual Meeting of the American Society of Gene Therapy, which is being held at the San Diego Convention Center in San Diego, CA, from Wednesday, May 27th through to Saturday, May 30th, 2009. Mr. Dondero will be presenting in the afternoon session on Thursday, May 28th. The American Society of Gene Therapy (ASGT) is a non-profit medical and professional organization that represents researchers and scientists devoted to the discovery of new gene and cell therapies. ASGT was established in 1996, and with more than 2,000 members in the United States and worldwide, ASGT is the largest association of individuals involved in gene and cell therapeutics. About Senesco Technologies, Inc. Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners" products. Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate a financing; the development of the Company"s gene technology; the approval of the Company"s patent applications; the successful implementation of the Company"s research and development programs and joint ventures; the success of the Company"s license agreements; the acceptance by the market of the Company"s products; the success of the Company"s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company"s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company"s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Senesco Technologies, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009